Influx Healthtech H1 FY27 Revenue Rises 28% on Mix Shift

Influx Healthtech Limited reported H1 FY27 revenue from operations of Rs 85.4 crore, up 27.9% year on year, led by nutraceutical revenue of Rs 75.3 crore and cosmetics revenue of Rs 6.9 crore. Earnings before interest, tax, depreciation and amortisation (EBITDA) rose 25.1% to Rs 18.3 crore, while EBITDA margin declined to 21.5% from 22.0%.

What drove Influx Healthtech's H1 FY27 revenue growth?

Influx Healthtech's revenue increase was principally driven by nutraceuticals, which rose by Rs 15.2 crore to Rs 75.3 crore in H1 FY27 from Rs 60.1 crore in H1 FY26. The segment remained the largest contributor, accounting for 88% of H1 FY27 revenue, although its reported revenue share fell from 90% a year earlier.

Cosmetics revenue rose to Rs 6.9 crore in H1 FY27 from Rs 3.4 crore in H1 FY26, increasing by Rs 3.5 crore. The increase lifted cosmetics' reported share of revenue to 8% from 5%, making it the segment with the largest change in revenue mix despite nutraceuticals supplying the greater rupee increase.

Ayurvedic revenue moved in the opposite direction, declining to Rs 2.1 crore from Rs 2.7 crore, while others increased to Rs 1.1 crore from Rs 0.5 crore. Others includes veterinary and homecare products. The four segment figures total Rs 85.4 crore in H1 FY27, compared with Rs 66.7 crore in H1 FY26 based on the rounded segment disclosures.

The reported mix shows a broader contribution from cosmetics alongside continued nutraceutical concentration. Ayurvedic's revenue share declined to 2% in H1 FY27 from 4% in H1 FY26, while others remained at 1%. The presentation does not identify customers, products or pricing actions behind the changes in any of the four segments.

How did Influx Healthtech's profitability change in H1 FY27?

Influx Healthtech reported EBITDA of Rs 18.3 crore in H1 FY27, up 25.1% year on year, but EBITDA margin declined by 0.5 percentage points to 21.5% from 22.0%. Revenue growth of 27.9% therefore exceeded the reported EBITDA growth rate during the half-year period.

Profit after tax (PAT) increased 20.0% year on year to Rs 12.0 crore, while PAT margin fell to 14.1% from 15.0% in H1 FY26. The reported progression was 27.9% revenue growth, 25.1% EBITDA growth and 20.0% PAT growth, alongside lower operating and net-profit margins.

Influx Healthtech also reported annualised H1 FY27 return measures. Return on equity was 21.4%, compared with 20.4% in FY26, while return on capital employed was 28.1%, compared with 25.8%. The company states that its H1 FY27 return measures and fixed-asset-turnover ratio have been annualised, meaning they are not presented as unannualised six-month ratios.

What changed in Influx Healthtech's operating and working-capital measures?

Influx Healthtech reduced debtor days to 72 in H1 FY27 from 84 in FY26, while its cash conversion cycle increased to 69 days from 64 days. The presentation therefore records a 12-day reduction in debtor days alongside a five-day increase in the broader cash conversion cycle.

Fixed asset turnover was 5.0 times in H1 FY27, compared with 5.3 times in FY26, and capacity utilisation was unchanged at 70%. Product range was reported at 2,345, down from 3,428 in FY26, whereas client retention remained at 98%. The presentation gives no reason for the lower product range or the movement in fixed asset turnover.

Influx Healthtech reported operations in 37 export countries, compared with 36 in FY26, and four manufacturing units, compared with three in FY25. One of the four manufacturing facilities is rented. The company also said it secured NSF certification for the second consecutive year and qualified for the final National Accreditation Board for Testing and Calibration Laboratories audit, without giving an audit completion date.

What capacity additions does Influx Healthtech plan for FY27?

Influx Healthtech said civil construction at its new 75,000 square foot Palghar facility was nearly complete, while interior work was under way and machinery had been delivered. Management said commercial production was on track to begin in the coming months, with staff recruitment and training under way. The presentation does not disclose the facility's cost, commissioning date or expected revenue contribution.

The company completed installation of additional automated bar lines for multilayer wafer bars and installed machinery for ready-to-drink (RTD) blister shots. At the Olahey Wellness unit, Influx Healthtech submitted an application for a Food Safety and Standards Authority of India manufacturing licence. The proposed daily capacity exceeds 5 lakh tablets, equivalent to about 15,000 bottles containing 30 units each, plus 15,000 bars.

Management said an FSSAI licence would position Influx Healthtech to launch wellness products using aseptic packaging and retort manufacturing processes. Management also said it anticipates 25% growth in FY27 with consistent profitability margins. The presentation does not specify whether the 25% target refers to revenue, profit or another financial measure.

Conclusion

Influx Healthtech's H1 FY27 performance combined revenue growth of 27.9% to Rs 85.4 crore with a shift in its segment mix. Nutraceuticals remained 88% of revenue after adding Rs 15.2 crore, while cosmetics added Rs 3.5 crore and increased its revenue share to 8% from 5%. EBITDA and PAT rose to Rs 18.3 crore and Rs 12.0 crore, respectively, but both reported margins were below H1 FY26 levels.

The next disclosed items to watch are the FSSAI licence outcome for Olahey Wellness and management's plan to start commercial production at the 75,000 square foot Palghar facility in the coming months. Management's stated FY27 target is 25% growth with consistent profitability margins, while the presentation leaves unresolved the target metric, the new facility's financial contribution and the timing of the final NABL audit.